Erlotinib Therapy
Reports on erlotinib therapy findings from Roswell Park Cancer Institute provide new insights
Published in Cancer Weekly, February 9th, 2010
Research findings, 'A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor,' are discussed in a new report. According to recent research from the United States, "IMPORTANCE OF THE FIELD: The epidermal growth factor receptor (EGFR) is a cell surface receptor for EGF and transforming growth factor-alpha which is overexpressed by a number of human tumors. Erlotinib, developed by OSI Pharmaceuticals, is an oral selective EGFR tyrosine kinase inhibitor, the only drug of its class approved for the treatment of locally advanced non-small cell lung cancer (NSCLC) after failure of at least one previous chemotherapy regimen and for first-line treatment...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2010-02-09)
More Articles from Cancer Weekly
- American College of Radiology / American Roentgen Ray Society
Virtual colonoscopy an effective colorectal cancer screening exam in Medicare age patients - Cytori Therapeutics
Cell-enriched fat grafts improve long term graft retention in preclinical study - Dana-Farber Cancer Institute
Genes found linked to breast cancer drug resistance could guide future treatment choices - Institute for Quality and Efficiency in Health Care
Women with breast cancer may benefit from autologous stem cell transplantation - JAMA and Archives Journals
Physical activity associated with healthier aging - Journal of the National Cancer Institute
News brief: Childhood survivors of CNS cancers and leukemia have lowered educational attainment - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
